3SBio (HKG:1530) said its 707 injection was granted a breakthrough therapy designation by China's National Medical Products Administration, according to a late Thursday bourse filing.
This designation provides benefits for 707's development as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small cell lung cancer, the filing stated.
Drugs with that designation are entitled to policy support, prioritized communication resources, enhanced guidance, and accelerated development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.